Abstracts tagged "Myositis"

Abstract Number: 0700 • ACR Convergence 2021
Clinical Outcomes in Idiopathic Inflammatory Myositis Within the Military Health System: A 15 Year Retrospective Review
David Mecham¹, William Moore¹ and Ian Ward², ¹Dwight D Eisenhower Army Medical Center, Fort Gordon, ²United States Army, Evans, GA
Background/Purpose: The Idiopathic Inflammatory Myopathies (IIM) are often difficult to treat, require chronic steroid therapy, and can remain active despite multiple treatment regimens. The objective…
Abstract Number: 0721 • ACR Convergence 2021
Timed Function Tests as Measures of Disease Activity and Functional Outcome in Inflammatory Myositis
saikumar dunga¹, Chengappa Kavadichanda² and VirSingh Negi³, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ²JIPMER, Pondicherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
Background/Purpose: Manual muscle testing (MMT) and Functional index 2(FI-2) are the usual methods in assessing disease activity and functional status in IIM1. Limitations of MMT8…
Abstract Number: 0441 • ACR Convergence 2021
A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
Pedro Machado¹, Richard Barohn², Michael McDermott³, Thomas Blaetter⁴, Tom Lloyd⁵, Aziz Shaibani⁶, Miriam Freimer⁷, Anthony Amato⁸, Emma Ciafaloni³, Sarah Jones⁹, Tahseen Mozaffar¹⁰, Summer Gibson¹¹, Matthew Wicklund¹², Todd Levine¹³, Claus Sundgreen⁴, Tim Carstensen⁴, Karen Bonefeld⁴, Anders Jørgensen⁴, Karina Phonekeo⁴, Andrew Heim¹⁴, Laura Herbelin¹⁴, Michael Hanna¹⁵ and Mazen Dimachkie¹⁴, ¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²University of Missouri - Columbia, Columbia, MO, ³University of Rochester, Rochester, NY, ⁴Orphazyme A/S, Copenhagen, Denmark, ⁵Johns Hopkins University, Baltimore, MD, ⁶Nerve and Musle Center, Houston, TX, ⁷Ohio State University, Columbus, OH, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Virginia, Charlottesville, VA, ¹⁰University of California Irvine, Irvine, CA, ¹¹University of Utah, Salt Lake City, UT, ¹²University of Colorado, Denver, CO, ¹³Phoenix Neurological Associates, Phoenix, AZ, ¹⁴University of Kansas Medical Center, Kansas City, KS, ¹⁵University College London, London, United Kingdom
Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
Abstract Number: 0702 • ACR Convergence 2021
Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing
Sarvar Nazir¹, Lisa Rider², Ira Targoff³, Stanley Naides⁴, Andrew Mammen⁵, Steven Greenberg⁶ and Adam Schiffenbauer⁵, ¹NIEHS, NIH, Bethesda, MD, ²NIEHS, NIH, Garrett Park, MD, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Self, Dana Point, CA, ⁵National Institutes of Health, Bethesda, MD, ⁶Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions. The presence of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) in patients…
Abstract Number: 0722 • ACR Convergence 2021
Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity
Alexandrine Mahoudeau¹, Céline Anquetil², Nozomu Tawara¹, Hossein Khademian¹, Damien Amelin¹, Yves Allenbach³ and Olivier Benveniste³, ¹Center of Research in Myology, Sorbonne University, Paris, France, ²Center of Research in Myology, Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France
Background/Purpose: In Idiopathic Inflammatory Myopathies (IIM) disease activity is very difficult to assess and IIM may induce severe muscle damage, especially in immune-mediated necrotizing myopathies…
Abstract Number: 0442 • ACR Convergence 2021
Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis
Kenichi Uto¹, Koji Ueda², Takaichi Okano¹, Kengo Akashi¹, Soshi Takahashi³, Yuji Nakamachi⁴, Takamitsu Imanishi¹, Seiji Kawano¹, Yoshihiko Yano⁵ and Jun Saegusa⁶, ¹Kobe University Hospital, Kobe, Japan, ²Japanese Foundation for Cancer Research, Tokyo, Japan, ³Shinko Hospital, Kobe, Japan, ⁴Kobe University School of Medicine, Kobe, Japan, ⁵Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, ⁶Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan
Background/Purpose: Extracellular vesicles (EVs), including exosomes and microvesicles, are small membrane vesicles released by almost all cell types and are found circulating in blood and…
Abstract Number: 0703 • ACR Convergence 2021
CD8 Positron Emission Tomography (PET/CT) Imaging with 89Zr-Df-IAB22M2C in Patients with Inclusion Body Myositis
Colin Quinn¹, Kelsey Moulton¹, Ron Korn², William Le³, Niti Goel⁴, Michael Farwell⁵ and Steven Greenberg⁶, ¹Department of Neurology, University of Pennsylvania, Philadelphia, PA, ²ImaginAb, Inglewood, CA, ³ImaginAb, Inc, Inglewood, CA, ⁴Abcuro, Inc., Newton,, MA, ⁵Department of Radiology, University of Pennsylvania, Philadelphia, PA, ⁶Brigham and Women's Hospital Department of Neurology, Boston, MA
Background/Purpose: Inclusion body myositis (IBM) is a slowly progressive autoimmune skeletal muscle disease for which no effective pharmacological therapy is available. A prominent feature of…
Abstract Number: 0743 • ACR Convergence 2021
Pain Interference, Fatigue, Physical Function as Outcome Measures in Adult Myositis: Updates on the Validation Process by the OMERACT Myositis Working Group
Dana DiRenzo¹, Ingrid de Groot², Helene Alexanderson³, Clifton Bingham¹, Ingrid E Lundberg⁴, Merrilee Needham⁵, Jin Kyun Park⁶, Malin Regardt³, Catherine Sarver⁷, Didem Saygin⁸, Yeong-Wook Song⁶, Lara Maxwell⁹, Dorcas Beaton¹⁰, Lisa Christopher-Stine¹ and Christopher Mecoli¹¹, ¹Johns Hopkins University, Baltimore, MD, ²patient research partner, Rotterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵Murdoch University, Perth, Australia, ⁶Seoul National University Hospital, Seoul, Republic of Korea, ⁷patient research partner, Baltimore, MD, ⁸University of Chicago, Chicago, IL, ⁹University of Ottawa, Ottawa, ON, Canada, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: People living with idiopathic inflammatory myositis (IIM) suffer impairments in health-related quality of life (HRQL), especially in the domains of pain interference, fatigue, and…
Abstract Number: 0444 • ACR Convergence 2021
COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey
Latika Gupta¹, James Lilleker², Vishwesh Agarwal³, Sinan Kardes⁴, Marcin Milchert⁵, Tamer Gheita⁶, Babur Salim⁷, Tsvetelina Velikova⁸, Oliver Distler⁹, Hector Chinoy¹⁰, Vikas Aggarwal¹ and Rohit Aggarwal¹¹, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Centre for Musculoskeletal Research,, Manchester, United Kingdom, ³Mahatma Gandhi Mission Medical College, Navi Mumbai, India, ⁴Medical Ecology and Hydroclimatology Istanbul Faculty of Medicine, Istanbul, Turkey, ⁵Katedra Reumatologii i Chorób Wewnętrznych, Klinika Chorób Wewnętrznych Reumatologii Diabetologii Geriatrii i Immunologii Klinicznej PUM, ul. Unii Lubelskiej 1, 71-252 Szczecin,, Szczecin, Poland, ⁶Cairo University, Egypt, Cairo, Egypt, ⁷Fauji Foundation Hospital, Rawalpindi, Pakistan, ⁸University Hospital Lozenetz, Sofia, Bulgaria, ⁹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ¹⁰University of Manchester, Salford, United Kingdom, ¹¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Numerous Covid-19 vaccines have demonstrated efficacy and safety against SARS-CoV-2 in general population. Despite favorable adverse effect (ADRs) profile of vaccines, there have been…
Abstract Number: 0706 • ACR Convergence 2021
Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis
Madison Grinnell¹, Emily Keyes², DeAnna Diaz², Thomas Vazquez³, Rui Feng⁴ and Victoria Werth², ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ³FIU Wertheim College of Medicine, Virginia Beach, VA, ⁴University of Pennsylvania Department of Biostatistics, Philadelphia, PA
Background/Purpose: Treatment of dermatomyositis (DM) typically follows a stepwise sequence starting with either methotrexate (MTX) or mycophenolate mofetil (MMF) after an inadequate response to antimalarial…
Abstract Number: 0756 • ACR Convergence 2021
Validation of Two Simple Patient-centered Outcome Measures for Virtual Monitoring of Patients with Idiopathic Inflammatory Myositis
R Naveen¹, Darpan R Thakare², Vikas Agarwal², Rohit Aggarwal³ and Latika Gupta¹, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Changing landscape of patient care from in-person to virtual telemedicine-based consultation in times of a global pandemic has necessitated a wider use of patient-centered…
Abstract Number: 0650 • ACR Convergence 2021
Use, Procurement Cost, and Adverse Events from IVIg Use in Rheumatic Disease
Francisca Lambert-Fliszar¹, Evelyne Vinet², Sasha Bernatsky¹ and Arielle Mendel³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Mont Royal, QC, Canada, ³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Intravenous immunoglobulin (IVIg) is used in several systemic rheumatic diseases due to postulated immunomodulatory properties. However, IVIg is a scarce and costly resource and…
Abstract Number: 0708 • ACR Convergence 2021
Cardiovascular Risk in Myositis Patients Compared to General Population – Preliminary Data from a Single-centre Cross-sectional Study
Sabina Oreska¹, Hana Storkanova¹, Maja Spiritovic², Barbora Hermankova³, Petr Cesak⁴, Jaroslav Kudlicka⁵, Vladimir Tuka⁶, Ondrej Mikes⁵, Martin Satny⁵, Eva Chytilova⁵, Zdislava Krupickova⁵, Michal Vrablik⁵, Karel Pavelka¹, Ladislav Senolt¹, Herman Mann¹, Jiri Vencovsky⁷ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ³Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁴Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charle, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid treatment, which can have a negative impact on metabolic disease, atherogenesis,…
Abstract Number: 1007 • ACR Convergence 2021
Vascular Deposition of Oxidized LDL Is Increased in Children with Untreated Juvenile Dermatomyositis
Jacob Spitznagle¹, Akadia Kacha-Ochana², Joan Cook-Mills³, Amer Khojah², Gabrielle Morgan⁴ and Lauren Pachman⁵, ¹Hospital for Special Surgery, New York, NY, ²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Indiana University School of Medicine, Departments of Pediatrics and Microbiology & Immunology, Indianapolis, IN, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic vasculopathy associated with metabolic derangements and possible increased risk for premature atherosclerosis. Oxidation of low-density lipoprotein (LDL) in…
Abstract Number: 0683 • ACR Convergence 2021
Predictors of Rapidly Progressive Interstitial Lung Disease and Mortality in Patients with Autoantibodies Against Melanoma Differentiation-Associated Protein 5 Dermatomyositis
Jacqueline So¹, Lai-Shan Tam², Priscilla Wong¹, Lydia Ho-Pui Tam¹, Tsz On Lam¹, Chi Chiu Mok³, Chi Hung To⁴, Yuen Kwan Chung⁴, Victor Tak Lung Wong⁵, Tsz Yuen Wu⁶, Roy Ho⁷, Wai Ling Li⁸, Chi Ho⁹ and Ho So¹⁰, ¹Prince of Wales Hospital, Hong Kong, Hong Kong, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic), ³Tuen Mun Hospital, Hong Kong, China, ⁴Pok Oi Hospital, Hong Kong, Hong Kong, ⁵Kwong Wah Hospital, Hong Kong, Hong Kong, ⁶Princess Margaret Hospital, Hong Kong, Hong Kong, ⁷Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁸Queen Mary Hospital, Hong Kong, Hong Kong, ⁹Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ¹⁰CUHK, Hong Kong, China
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) positive dermatomyositis (DM) is associated with rapidly progressive interstitial lung disease (RP-ILD) and high mortality. This multi-centre retrospective study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.